UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 6-K

 

 

REPORT OF FOREIGN PRIVATE ISSUER

 

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

 

August 6, 2026

 

 

NOVO NORDISK A/S

 (Exact name
of Registrant as specified in its charter)

 

 

Novo Allé 1

DK- 2880, Bagsvaerd

Denmark

(Address of principal executive offices)

 

 

Indicate by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F

 

Form 20-F ☒     
     Form 40-F ☐

  

 

 

 

 

 

 

 

Trading in Novo Nordisk shares by board members, executives and associated persons

 

Bagsværd, Denmark, 6 August 2026 —
This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members,
executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s
board members, executives and their associated persons have reported the transactions to Novo Nordisk.

 

 

 

 

 

 

 

1
Details of the person discharging managerial responsibilities/person closely associated

a)

Name of the Board

member/Executive/Associated Person

DÉSIRÈE JANTZEN ASGREEN

2
Reason for the notification

a)
Position/status
Member of the Board of Directors

b)
Initial notification/Amendment
Initial notification

3
Details of the issuer

a)
Name
Novo Nordisk A/S

b)
LEI
549300DAQ1CVT6CXN342

4
Details of the transaction(s)

a)

Description of the financial instrument,
type of instrument,

Shares
 
 

Identification code
Novo Nordisk B DK0062498333
 

b)
Nature of the transaction

Other transaction (vesting of shares in accordance
with Restricted Shares programme – Novo Nordisk 100th Anniversary Shares)

c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 

DKK 294.30
74

 

d)

Aggregated information

· Aggregated volume

·  Price

74 shares

DKK 21,778.20

e)
Date of the transaction
2026-08-05

f)
Place of the transaction
Outside a trading venue

 

 

1
Details of the person discharging managerial responsibilities/person closely associated

a)

Name of the Board

member/Executive/Associated Person

ELISABETH DAHL CHRISTENSEN

2
Reason for the notification

a)
Position/status
Member of the Board of Directors

b)
Initial notification/Amendment
Initial notification

3
Details of the issuer

a)
Name
Novo Nordisk A/S

b)
LEI
549300DAQ1CVT6CXN342

4
Details of the transaction(s)

a)

Description of the financial instrument,
type of instrument,

Shares
 
 

Identification code
Novo Nordisk B DK0062498333
 

b)
Nature of the transaction

Other transaction (vesting of shares in accordance
with Restricted Shares programme – Novo Nordisk 100th Anniversary Shares)

c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 

DKK 294.30
74

 

d)

Aggregated information

·  Aggregated volume

·  Price

74 shares

DKK 21,778.20

e)
Date of the transaction
2026-08-05

f)
Place of the transaction
Outside a trading venue

 

 

1
Details of the person discharging managerial responsibilities/person closely associated

a)

Name of the Board

member/Executive/Associated Person

METTE BØJER JENSEN

2
Reason for the notification

a)
Position/status
Member of the Board of Directors

b)
Initial notification/Amendment
Initial notification

3
Details of the issuer

a)
Name
Novo Nordisk A/S

b)
LEI
549300DAQ1CVT6CXN342

4
Details of the transaction(s)

a)

Description of the financial instrument,
type of instrument,

Shares
 
 

Identification code
Novo Nordisk B DK0062498333
 

b)
Nature of the transaction

Other transaction (vesting of shares in accordance
with Restricted Shares programme – Novo Nordisk 100th Anniversary Shares)

c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 

DKK 294.30
74

 

d)

Aggregated information

·  Aggregated volume

·  Price

74 shares

DKK 21,778.20

e)
Date of the transaction
2026-08-05

f)
Place of the transaction
Outside a trading venue

 

 

1
Details of the person discharging managerial responsibilities/person closely associated

a)

Name of the Board

member/Executive/Associated Person

SEMSI KILIC MADSEN

2
Reason for the notification

a)
Position/status
Member of the Board of Directors

b)
Initial notification/Amendment
Initial notification

3
Details of the issuer

a)
Name
Novo Nordisk A/S

b)
LEI
549300DAQ1CVT6CXN342

4
Details of the transaction(s)

a)

Description of the financial instrument,
type of instrument,

Shares
 
 

Identification code
Novo Nordisk B DK0062498333
 

b)
Nature of the transaction

Other transaction (vesting of shares in accordance
with Restricted Shares programme – Novo Nordisk 100th Anniversary Shares)

c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 

DKK 294.30
74

 

d)

Aggregated information

·  Aggregated volume

·  Price

74 shares

DKK 21,778.20

e)
Date of the transaction
2026-08-05

f)
Place of the transaction
Outside a trading venue

 

 

1
Details of the person discharging managerial responsibilities/person closely associated

a)

Name of the Board

member/Executive/Associated Person

EMIL KONGSHØJ LARSEN

2
Reason for the notification

a)
Position/status

Executive Vice President, International
Operations

b)
Initial notification/Amendment
Initial notification

3
Details of the issuer

a)
Name
Novo Nordisk A/S

b)
LEI
549300DAQ1CVT6CXN342

4
Details of the transaction(s)

a)

Description of the financial instrument,
type of instrument,

Shares
 
 

Identification code
Novo Nordisk B DK0062498333
 

b)
Nature of the transaction

Other transaction (vesting of shares in accordance with Restricted Shares programme
– Novo Nordisk 100th Anniversary Shares)

c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 

DKK 294.30
74

 

d)

Aggregated information

·  Aggregated volume

·  Price

74 shares

DKK 21,778.20

e)
Date of the transaction
2026-08-05

f)
Place of the transaction
Outside a trading venue

 

 

1
Details of the person discharging managerial responsibilities/person closely associated

a)

Name of the Board

member/Executive/Associated Person

KARSTEN MUNK KNUDSEN

2
Reason for the notification

a)
Position/status

Executive Vice President, Chief Financial
Officer (CFO)

b)
Initial notification/Amendment
Initial notification

3
Details of the issuer

a)
Name
Novo Nordisk A/S

b)
LEI
549300DAQ1CVT6CXN342

4
Details of the transaction(s)

a)

Description of the financial instrument,
type of instrument,

Shares
 
 

Identification code
Novo Nordisk B DK0062498333
 

b)
Nature of the transaction

Other transaction (vesting of shares in accordance
with Restricted Shares programme – Novo Nordisk 100th Anniversary Shares)

c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 

DKK 294.30
74

 

d)

Aggregated information

·  Aggregated volume

·  Price

74 shares

DKK 21,778.20

e)
Date of the transaction
2026-08-05

f)
Place of the transaction
Outside a trading venue

 

 

1
Details of the person discharging managerial responsibilities/person closely associated

a)

Name of the Board

member/Executive/Associated Person

KASPER BØDKER MEJLVANG

2
Reason for the notification

a)
Position/status

Executive Vice President, Global Manufacturing
& Supply

b)
Initial notification/Amendment
Initial notification

3
Details of the issuer

a)
Name
Novo Nordisk A/S

b)
LEI
549300DAQ1CVT6CXN342

4
Details of the transaction(s)

a)

Description of the financial instrument,
type of instrument,

Shares
 
 

Identification code
Novo Nordisk B DK0062498333
 

b)
Nature of the transaction

Other transaction (vesting of shares in accordance
with Restricted Shares programme – Novo Nordisk 100th Anniversary Shares)

c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 

DKK 294.30
74

 

d)

Aggregated information

·  Aggregated volume

·  Price

74 shares

DKK 21,778.20

e)
Date of the transaction
2026-08-05

f)
Place of the transaction
Outside a trading venue

 

 

1
Details of the person discharging managerial responsibilities/person closely associated

a)

Name of the Board

member/Executive/Associated Person

MAZIAR MIKE DOUSTDAR

2
Reason for the notification

a)
Position/status
President and CEO

b)
Initial notification/Amendment
Initial notification

3
Details of the issuer

a)
Name
Novo Nordisk A/S

b)
LEI
549300DAQ1CVT6CXN342

4
Details of the transaction(s)

a)

Description of the financial instrument,
type of instrument,

Shares
 
 

Identification code
Novo Nordisk B DK0062498333
 

b)
Nature of the transaction

Other transaction (vesting of shares in accordance with Restricted Shares programme
– Novo Nordisk 100th Anniversary Shares)

c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 

DKK 294.30
74

 

d)

Aggregated information

·  Aggregated volume

·  Price

74 shares

DKK 21,778.20

e)
Date of the transaction
2026-08-05

f)
Place of the transaction
Outside a trading venue

 

 

1
Details of the person discharging managerial responsibilities/person closely associated

a)

Name of the Board

member/Executive/Associated Person

MARTIN HOLST LANGE

2
Reason for the notification

a)
Position/status

Executive Vice President, R&D and Chief
Scientific Officer (CSO)

b)
Initial notification/Amendment
Initial notification

3
Details of the issuer

a)
Name
Novo Nordisk A/S

b)
LEI
549300DAQ1CVT6CXN342

4
Details of the transaction(s)

a)

Description of the financial instrument,
type of instrument,

Shares
 
 

Identification code
Novo Nordisk B DK0062498333
 

b)
Nature of the transaction

Other transaction (vesting of shares in accordance
with Restricted Shares programme – Novo Nordisk 100th Anniversary Shares)

c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 

DKK 294.30
74

 

d)

Aggregated information

·  Aggregated volume

·  Price

74 shares

DKK 21,778.20

e)
Date of the transaction
2026-08-05

f)
Place of the transaction
Outside a trading venue

 

 

1
Details of the person discharging managerial responsibilities/person closely associated

a)

Name of the Board

member/Executive/Associated Person

THILDE GYNTHE BØGEBJERG KRØYER

2
Reason for the notification

a)
Position/status

Executive Vice President, Enterprise IT &
Quality

b)
Initial notification/Amendment
Initial notification

3
Details of the issuer

a)
Name
Novo Nordisk A/S

b)
LEI
549300DAQ1CVT6CXN342

4
Details of the transaction(s)

a)

Description of the financial instrument,
type of instrument,

Shares
 
 

Identification code
Novo Nordisk B DK0062498333
 

b)
Nature of the transaction

Other transaction (vesting of shares in accordance
with Restricted Shares programme – Novo Nordisk 100th Anniversary Shares)

c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 

DKK 294.30
74

 

d)

Aggregated information

·  Aggregated volume

·  Price

74 shares

DKK 21,778.20

e)
Date of the transaction
2026-08-05

f)
Place of the transaction
Outside a trading venue

 

 

1
Details of the person discharging managerial responsibilities/person closely associated

a)

Name of the Board

member/Executive/Associated Person

TANIA SABROE

2
Reason for the notification

a)
Position/status

Executive Vice President, People,
Organisation & Corporate Affairs

b)
Initial notification/Amendment
Initial notification

3
Details of the issuer

a)
Name
Novo Nordisk A/S

b)
LEI
549300DAQ1CVT6CXN342

4
Details of the transaction(s)

a)

Description of the financial instrument,
type of instrument,

Shares
 
 

Identification code
Novo Nordisk B DK0062498333
 

b)
Nature of the transaction

Other transaction (vesting of shares in accordance
with Restricted Shares programme – Novo Nordisk 100th Anniversary Shares)

c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 

DKK 294.30
74

 

d)

Aggregated information

·  Aggregated volume

·  Price

74 shares

DKK 21,778.20

e)
Date of the transaction
2026-08-05

f)
Place of the transaction
Outside a trading venue

 

Novo Nordisk is a leading global healthcare
company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our
heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately
cure disease. Novo Nordisk employs about 66,700 people in 80 countries and markets its products in around 170 countries. Novo Nordisk’s
B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit
novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.

 

 

 

Contacts for further information

 

Media:
 

Ambre James-Brown

+45 3079 9289

abmo@novonordisk.com

Liz Skrbkova
(US)

+1 609 917 0632

lzsk@novonordisk.com

 
 

Investors:
 

Michael Novod

+45 3075 6050

nvno@novonordisk.com

Sina Meyer

+45 3079 6656

azey@novonordisk.com

 
 

Alex Bruce

+45 3444 2613

axeu@novonordisk.com

Mads Berner Bruun

+45 3075 2936

mbbz@novonordisk.com

 
 

Christoffer Togo Solgaard-Tullin

+45 3079 1471

cftu@novonordisk.com

Ida Schaap Melvold

+45 3077 5649

idmg@novonordisk.com

 
 

Frederik Taylor Pitter (US)

+1 609 613 0568

fptr@novonordisk.com

 

 

 

  

 

 

 

Novo Nordisk A/S

Investor Relations

Novo Alle 1

2880 Bagsværd

Denmark

Telephone:

+45 4444 8888

www.novonordisk.com
CVR no: 24 25 67 90

   Company
announcement No 49 / 2026

 

 

 

SIGNATURES

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

 

Date: August 6, 2026

 

NOVO NORDISK A/S

 

Maziar Mike Doustdar

Chief Executive Officer